Cancer Immunotherapy and Biomarkers

PD-L1 deletion or blockade regulate macrophage antigen presentation and checkpoint molecule surface levels

This study investigates how PD-L1 deletion or blockade affects macrophage antigen presentation and checkpoint molecule levels in different polarization states.

Colorectal cancers with distinct metastatic potential trigger divergent early T cell responses

This study shows that colorectal cancers with different metastatic potential trigger distinct early T cell responses, with non-metastatic tumors inducing cytotoxic T cells and pro-metastatic tumors causing hypoactivated T cells.

Experimental type 1 diabetes metabolically rejuvenates CD8+ T cells for improved control of tumor growth through an IGF1-IGF1R axis

This study shows that experimental type 1 diabetes enhances CD8+ T cell function via the IGF1-IGF1R axis, leading to better tumor control.

γδ T cells modulate anti-tumor immunity in small cell lung cancer

This study identifies γδ T cell infiltration in SCLC and shows their anti-tumor activity, suggesting they could be therapeutic targets.

JAK-STAT Pathway Heterogeneity Governs Immunotherapy Response in Breast Cancer

This paper investigates JAK-STAT pathway heterogeneity in breast cancer and finds that high JSP activity correlates with improved immunotherapy response, particularly in triple-negative breast cancer.

A gastric microbial chromatin remodeler drives gastric cancer progression and immune evasion by reprogramming the host epigenome

This study identifies Streptococcus anginosus as a gastric cancer driver that uses a chromatin remodeler to reprogram host epigenomes and promote immune evasion.

Targeting the Myeloid Immune Checkpoint ILT3 (LILRB4) with Small Molecules Enables Reprogramming of Suppressive Tumor Immunity

This study identifies small molecule modulators of ILT3, a myeloid immune checkpoint, showing anti-tumor efficacy in preclinical models.

Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemo-immunotherapy in triple-negative breast cancer

The paper identifies distinct immune states in TNBC patients based on treatment and response, linking peripheral immune dynamics to therapeutic outcomes.

Dynamic Tumor Immune Microenvironment Remodeling Predicts Response of Checkpoint Inhibitor Therapy

The paper maps treatment-associated changes in the tumor immune microenvironment using single-cell RNA sequencing and identifies transition patterns that predict response to checkpoint inhibitor therapy.

Integrating Mathematical and Mouse Models Identifies T regulatory Cell Influx as a Key Determinant of Acquired Resistance to PD-1 Immunotherapy

mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment.

This study shows that mTOR inhibition with everolimus enhances antitumor immune responses in TP53-mutant HNSCC by altering the tumor microenvironment.

Transposable Elements and Homotypic Niches Drive Immune Dynamics and Resistance in Melanoma Epigenetic-based immunotherapy

This study identifies how epigenetic changes and spatial clustering influence immune dynamics and therapy resistance in melanoma through single-cell and spatial transcriptomics analyses.

TSTScope Unifies Single-Cell Multi-Omics to Identify Functional T Cell States Predictive of Immunotherapy Response

TSTScope integrates single-cell transcriptomics and T-cell receptor data to identify functional T cell states predictive of immunotherapy response, finding that functional state, not abundance, determines treatment outcomes.

Trans-presentation of IL-15 by IL15Rα attenuates tumor immune surveillance and is dispensable for IL-15-dependent tumor growth control

This study shows IL-15R restrains tumor immune surveillance but is dispensable for IL-15-dependent tumor growth control, while IL-15 has minimal role in spontaneous tumor development.

Harnessing Tumor-Specific Transcript Diversity Uncovers a Shared Neoantigen Reservoir for Pancreatic Ductal Adenocarcinoma

This paper introduces NeoAPP, a tool to identify tumor-specific transcript-derived neoantigens in PDAC, revealing a large neoantigen reservoir that could improve immunotherapy.

CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer

This study identifies Dusp5 and Zfp219 as key regulators of age-related T cell dysfunction using CRISPR screens and shows their potential as therapeutic targets.

Direct Small Molecule Modulation of LILRB4 (ILT3) Restores Anti-Tumor Immunity In Vivo and in Patient-Derived Cells

This study identifies GL-4512, a small molecule modulator of LILRB4, which restores anti-tumor immunity in vivo and in patient-derived cells by disrupting immunosuppressive signaling.

Leveraging TNFR2 for antitumour immunity: T reg depletion and myeloid reprogramming versus T cell costimulation

This paper evaluates two TNFR2-targeting antibodies, showing ligand-blocking antibodies deplete T regs and reprogram myeloid cells, while agonists directly co-stimulate T and NK cells, both leading to anti-tumor effects.

Decitabine reverses innate immune gene suppression in rare melanomas

This study identifies immune evasion mechanisms in rare melanomas and shows that decitabine reactivates innate immune pathways, improving immune responsiveness.

Decoding Neoantigen-encoding Tumor-Specific Transcripts Unveils a Shared Target Reservoir for Immunotherapy in Hepatocellular Carcinoma

This paper identifies neoantigen-encoding tumor-specific transcripts (neoTSTs) in hepatocellular carcinoma, showing they are more abundant and immunogenic than mutation-derived neoantigens, and demonstrate therapeutic potential in preclinical models.

MAPK/ERK signaling in gliomas modulates interferon responses, T cell recruitment, enhances tumor-microglia crosstalk, and drives immune checkpoint blockade efficacy.

This study identifies the MAPK/ERK pathway as a key regulator of glioma susceptibility to immune checkpoint blockade, showing it modulates interferon responses, T cell recruitment, and tumor-microglia interactions.

Inhibition of KDEL receptors remodels the tumor microenvironment for robust T cell independent tumor regression

The paper shows that inhibiting KDELR2 in tumor cells promotes tumor regression through innate immune activation, independent of T cells, and primes anti-tumor T cells for future challenges.

Quantifying PD1 saturation by PDL1 in tumor tissue using a novel RNA aptamer-based assay

This paper introduces a novel RNA aptamer-based assay to quantify PD1 saturation by PDL1 in tumor tissue and demonstrates its correlation with PD1-mediated signaling and clinical relevance.

Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer

This study shows tumor suppressor genotype affects immune cell recruitment and tumor growth in KRAS-driven lung cancer with varying neoantigen expression.

Stromal cell subsets modulate T-cell infiltration in early breast cancer

The paper identifies stromal cell subsets in breast cancer that influence T-cell infiltration and patient outcomes through spatial and clinical analysis.

MSC-delivered High-Affinity Variants of soluble PD1 lead to tumour regression

This paper develops a cell-based immune checkpoint therapy using MSCs to deliver a high-affinity sPD1 variant, showing anti-tumour activity in a mouse model.

Immunopeptidomics-guided identification of functional neoantigens in non-small cell lung cancer

The paper identifies functional neoantigens in NSCLC patients using immunopeptidomics, achieving an 83% success rate in eliciting immune responses.

GraphTME: a framework for predicting response to immune checkpoint inhibitors by interpreting cell-cell interactions in the tumour microenvironment using spatial transcriptomics of tumour tissue

GraphTME predicts immune checkpoint inhibitor response by analyzing spatial cell-cell interactions in tumor microenvironments using spatial transcriptomics data.

Effector T cells in poorly perfused tumor regions exhibit a distinct signature of augmented IFN response and reduced PD-1 expression

The paper identifies distinct gene signatures in effector T cells from poorly perfused tumor regions, showing enhanced IFN response and reduced PD-1 expression.

Viral mimicry redirects immunosuppressed colorectal tumour landscapes towards a proinflammatory and CMS1-like regenerative state

This study shows that poly(I:C) treatment in CMS4 colorectal tumors induces a pro-inflammatory, CMS1-like regenerative state and identifies biomarkers for predicting therapeutic response.